Juglanin

Juglanin is a flavonol that has been found in J. mandshurica and has diverse biological activities.^1,2,3 It reduces the levels of reactive oxygen species (ROS) increased by oscillatory shear stress (OSS) in human aortic endothelial cells (HAECs) when used at concentrations of 2.5 and 5 µM.¹ It also reduces OSS-induced increases in VCAM-1 and E-selectin protein levels in HAECs and decreases the attachment of THP-1 monocytes to HAECs. Juglanin (2.5, 5, and 10 µM) inhibits the proliferation of MCF-7 human breast cancer cells, as well as induces JNK activation, autophagosome formation, apoptosis, and cell cycle arrest at the G₂/M phase in the same cells.² It reduces tumor growth in an MCF-7 mouse xenograft model when administered at doses of 10 and 20 mg/kg. Juglanin (15 and 30 mg/kg) reduces body weight, renal fibrosis, and blood glucose levels, as well as serum and renal levels of Tnf-α, Il-1β, Il-6, and chemokine (C-C motif) ligand 2 (Ccl2), and improves glucose tolerance in a mouse model of high-fat diet- and obesity-induced kidney disease.³

WARNING This product is not for human or veterinary use.

1. Zhao, J., Quan, X., Xie, Z., et al. Juglanin suppresses oscillatory shear stress-induced endothelial dysfunction: An implication in atherosclerosis. Int. Immunopharmacol. 89(Pt B), 107048 (2020).

2. Sun, Z.-L., Dong, J.-L., and Wu, J. Juglanin induces apoptosis and autophagy in human breast cancer progression via ROS/JNK promotion. Biomed. Pharmacother. 85, 303-312 (2017).

3. Li, Q., Ge, C., Tan, J., et al. Juglanin protects against high fat diet-induced renal injury by suppressing inflammation and dyslipidemia via regulating NF-κB/HDAC3 signaling. Int. Immunopharmacol. 95, 107340 (2021).